A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases

Rapid point-of-care, antibody-based testing is not available for the diagnosis of autoimmune and most infectious diseases. For detecting autoantibodies associated with most autoimmune conditions, fluid-phase immunoprecipitation assays are required. However, these assays usually involve radioactivity and are not feasible for point-of-care applications. The subject invention describes methods of using neodymium magnet for diagnosis of infectious and autoimmune diseases including lupus, Sjögren's syndrome, type I diabetes, HIV and Lyme disease. The assay takes 3.5 minutes, is highly efficient, and has low background.

Potential Commercial Applications: Competitive Advantages:
  • A rapid assay for point-of-care diagnosis of infectious and autoimmune diseases.
  • Applications to different assay platforms, such as a portable, commercially available hand-held luminometer or an automated, high-throughput device.
  • Highly efficient, rapid, and easy to perform.
  • Low background signals.

Development Stage:
  • Early-stage
  • In vitro data available
  • Prototype

Related Invention(s):


Peter Burbelo (NIDCR)  ➽ more inventions...

Intellectual Property:
US Pat: 10,564,152 issued 2020-02-18
PCT Application No. PCT/US2016/046037 filed on 2016-08-08
US Application No. 15/756,012 filed on 2018-02-27
US Application No. 16/776,831 filed on 2020-01-30

Burbelo PD, et al. PMID 25241936
Burbelo PD, et al. PMID 25203116
Burbelo PD, et al. PMID 21679112
Burbelo PD, et al. PMID 19812534

Collaboration Opportunity:

The National Institute of Dental and Craniofacial Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize using neodymium magnet for rapid diagnosis. For collaboration opportunities, please contact David Bradley, Ph.D. at bradleyda@nidcr.nih.gov.

Licensing Contact:
Ediz Yonter, M.S., J.D.
Email: ediz.yonter@nih.gov
Phone: 301-443-5605

OTT Reference No: E-190-2015-0
Updated: May 6, 2018